Related Experiment Videos

Transactivation-deficient DeltaTA-p73 acts as an oncogene

Thorsten Stiewe1, Sonja Zimmermann, Andreja Frilling

  • 1Centre for Cancer Research and Cancer Therapy, Institute of Molecular Biology, University of Essen, Medical School, D-45122 Essen, Germany.

Cancer Research
|July 5, 2002
PubMed

Insights

Truncated p73 proteins (DeltaTA-p73), lacking transactivation function, are overexpressed in human cancers. DeltaTA-p73 promotes malignant transformation and tumor growth, indicating an oncogenic role for the TP73 gene in cancer development.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • The p53-family member p73 shares homology with p53.
  • Evidence suggests p73 may not function as a classical tumor suppressor.
  • The role of truncated p73 isoforms in cancer is largely unexplored.

Purpose of the Study:

  • To investigate the function of NH(2)-terminally truncated, transactivation-deficient p73 proteins (DeltaTA-p73).
  • To determine if DeltaTA-p73 overexpression contributes to cancer development.
  • To provide experimental evidence for the oncogenic potential of DeltaTA-p73.

Main Methods:

  • Analysis of DeltaTA-p73 expression in human cancer cells.
  • Malignant transformation assays using NIH3T3 fibroblasts.
  • Tumorigenicity studies in nude mice.

Main Results:

  • Overexpression of DeltaTA-p73 was observed in human cancer cells.
  • DeltaTA-p73 overexpression induced malignant transformation of fibroblasts.
  • DeltaTA-p73 promoted tumor growth in vivo.

Conclusions:

  • The TP73 gene can acquire oncogenic activity through increased expression of truncated isoforms.
  • DeltaTA-p73 possesses oncogenic functions, contributing to tumor development.
  • The findings suggest that DeltaTA-p73 is actively selected for during tumorigenesis.

Related Concept Videos